Document 0652
 DOCN  M9480652
 TI    [Opportunistic infections in AIDS: the benefits of an umbrella strategy.
       From an interview with Professor Willy Rozenbaum]
 DT    9410
 AU    Rozenbaum W; Service des Maladies Infectieuses, Hopital Rothschild,
       Pris.
 SO    Allerg Immunol (Paris). 1994 Apr;26(4):153-5. Unique Identifier :
       AIDSLINE MED/94304499
 AB    Availability to practitioners of a treatment for infections by atypical
       mycobacteria by Ansatipine should produce a reduction or delay in the
       frequency of opportunistic infections in AIDS, which are a heavy burden
       on the future of the patients and seriously after their quality of life.
       Today, the practice of prescribing Ansatipine increase the prophylactic
       strategy for opportunistic infections in AIDS, or the Umbrella strategy.
       This can only improve the possible therapies for practitioners who are
       faced with the complexity of the disease and bring real benefit to the
       patients. Distribution of Ansatipine to town pharmacies is a new step in
       this direction.
 DE    AIDS-Related Opportunistic Infections/MICROBIOLOGY/*PREVENTION &
       CONTROL/PARASITOLOGY  English Abstract  Human  Pharmacies  Quality of
       Life  Rifabutin/SUPPLY & DISTRIBUTION/*THERAPEUTIC USE  INTERVIEW
       JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).